PUBLISHER: Polaris Market Research | PRODUCT CODE: 1339319
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1339319
The global virtual clinical trials market size is expected to reach USD 28,544.08 million by 2032, according to a new study by Polaris Market Research. The report "Virtual Clinical Trials Market Share, Size, Trends, Industry Analysis Report, By Design (Observational Trials, Interventional Trials, and Expanded Access Trials); By Indication; By Phases; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Increased research and development activities, healthcare digitization, and the adoption of telehealth drive the virtual clinical trials market. These factors enable seamless integration of virtual trials, remote participation, and monitoring in clinical studies. Collaborations between organizations and supportive government initiatives contribute to the market's growth. These trends emphasize the industry's focus on virtual methods, which offer flexibility, efficiency, and improved patient engagement in clinical trials.
The COVID-19 pandemic has profoundly impacted clinical trials, leading to increased adoption of virtual trials. Challenges in patient recruitment and retention have been observed, and disruptions to ongoing trials have occurred. Virtual trials emerged as a crucial solution during the pandemic, allowing participants to participate from home and ensuring research continuity when site visits were impossible.
Virtual trials offer numerous advantages, including remote data collection, increased participant engagement, and larger population inclusion. They minimize risks associated with in-person visits and reduce the burden on participants, coordinators, and investigators. By leveraging virtual methods, the clinical trials industry can overcome challenges, improve efficiency, and facilitate prompt and effective data collection.
The interventional design segment dominated the market in 2022, driven by the need for innovative medications and the increased demand for trials amidst the COVID-19 pandemic.
The oncology segment led the market in 2022 and is expected to maintain its dominance due to the rising incidence of cancer and the adoption of virtual trials for patient safety during the COVID-19 pandemic.
North America holds a significant revenue share in the global virtual clinical trials market, driven by major pharmaceutical companies, government investments, and collaborations like Janssen and PRA Health Sciences' decentralized Canagliflozin study for heart failure patients.
The global key market players include: LEO Innovation Lab, Covance Inc., CRF Health, Oracle Corporation, Medable, Inc., Paraxel International, Clinical Ink, Inc., PRA Health Sciences, Science 37, and ICON plc.
Polaris Market Research has segmented the Virtual Clinical Trials market report based on design, indication, phases, and region: